Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Kidney International - Volume 85, Issue 4, April 2014, Pages 723-727

Steven J. Rosansky, Richard J. Glassock,